Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development Preclinical findings demonstrate high potential of the PAR2 biased negative allosteric modulator (NAM) […]
Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity Strasbourg, France – Montreal, […]
– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. – RTX001 has recently entered into a Phase […]
New results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months1 (4.1 – NE) – with one […]
MATCH Phase 2 data underscores significant potential of macrophage cell therapy treatment for advanced liver cirrhosis Resolution Therapeutics presents novel discovery platform for engineered macrophage cell therapy to enhance therapeutic efficacy Edinburgh and London, UK, 5 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver […]
